Tetraphase Pharmaceuticals is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize tetracyclines for serious conditions, including bacterial infections caused by multidrug-resistant (MDR) bacteria. Co.'s product, Xerava (eravacycline), is an intravenous, antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections. In addition to Xerava, Co. has also developed other fluorocycline antibiotic compounds, TP-6076 and TP-271, and TP-2846, a tetracycline for the treatment of acute myeloid leukemia. The TTPH stock yearly return is shown above.
The yearly return on the TTPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TTPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|